Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.57 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.54 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.54 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.54 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.54 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.54 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386411 | 0.92 | DRD4 (0.66) | SIGMAR1SLC6A12MCHR1TMEM97POLB | |
| SCHEMBL2389917 | 0.91 | MCHR1 (0.70) | SIGMAR1SLC6A12MCHR1TMEM97POLB | |
| SCHEMBL12227453 | 0.90 | POLB (0.61) | SIGMAR1SLC6A12MCHR1TMEM97POLB | |
| SCHEMBL2387674 | 0.90 | POLB (0.64) | SIGMAR1SLC6A12MCHR1TMEM97POLB | |
| SCHEMBL4441428 | 0.90 | SLC6A12 (0.60) | SIGMAR1SLC6A12MCHR1TMEM97POLB | |
| SCHEMBL2389650 | 0.90 | UTS2R (0.65) | SIGMAR1SLC6A12MCHR1TMEM97UTS2R | |
| SCHEMBL2394067 | 0.90 | DRD4 (0.61) | SIGMAR1SLC6A12MCHR1TMEM97POLB | |
| SCHEMBL2390049 | 0.89 | DRD4 (0.67) | SIGMAR1SLC6A12MCHR1TMEM97POLB | |
| SCHEMBL4428825 | 0.89 | DRD4 (0.61) | SIGMAR1SLC6A12MCHR1TMEM97POLB | |
| SCHEMBL2388982 | 0.89 | DRD4 (0.64) | SIGMAR1SLC6A12MCHR1TMEM97POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079694-B1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | claimed |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | claimed |
| EP-2079694-B1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2079694-B1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9181220-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181220-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-8012955-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012955-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012955-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| EP-2079694-A1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | Rigel Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008083124-A1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008083124-A1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | SIGMAR1 3482/4885SLC6A12 4494/4885MCHR1 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.